It has been shown that anti-TNF therapy shifted the diversity of fecal microbiota in patients with IBD toward that of healthy individuals, but levels of butyrate and substrates involved in butyrate synthesis in fecal samples were significantly reduced in non-responders, which suggested the insufficient consumption of dietary fiber in non-responders [165]. The gene discussed is TNF; the disease is irritable bowel syndrome.